U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07445919) titled 'A Phase II Clinical Study to Evaluate SM17 in Participants With Moderate to Severe Atopic Dermatitis' on Feb. 13.
Brief Summary: This trial is a phase 2, randomized, double-Blind, placebo-Controlled, dose-finding clinical study conducted in participants with moderate-to-severe atopic dermatitis.
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics , and pharmacodynamics of SM17 (subcutaneous injection) in participants with moderate to severe atopic dermatitis.
Study Start Date: April 05
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
BIOLOGICAL: SM17 for subcutaneous injection...